Advanced Perfusion Diagnostics
APD's mission is to improve the management of critically ill and high-risk patients through perfusion monitoring.
APD develops a new single-use device for non-invasive and continuous assessment of microcirculation in the critical care and surgical settings. The APD product will detect early signs of sepsis hours, if not days, before the tests currently used and the clinical symptoms. It is based on subtle changes in the urethral perfusion. Impairment of local microcirculation during septic shock is a triggering factor for multi-organ dysfunction syndrome and subsequent death. Despite its therapeutic importance, assessment of microcirculation remains difficult, with only non-continuous and deferred measurements when available.
After going through pre-clinical validation, First-in-Man clinical trials and receiving CE mark in 2016 for an initial version of the product, APD was acquired by Vygon in 2019.